Home›Earnings›Results›Johnson & Johnson posts 5.9% Q3 revenue growth and rai…

Johnson & Johnson posts 5.9% Q3 revenue growth and raises guidance

J&J said the OTTAVA robotic surgical system, approved for limited but expanding use in the US, is central to its long-term outlook.

Reported · Written up by our desk · Results

Johnson & Johnson reported Q3 revenue growth of 5.9% to $25.4 billion, and the company also raised its guidance, according to MarketBeat Ratings.

The outlet linked the outlook to J&J’s OTTAVA surgical system, described as a table-top integrated robotic device approved for limited but expanding use in the United States, and positioned as a key part of its longer-term medtech trajectory.

MarketBeat Ratings said OTTAVA makes up a small portion of revenue today, but it is central to the company’s long-term plan, including a slow acceleration toward double-digit top-line growth and wider margins.

The story also noted OTTAVA is expected to compete directly with Intuitive Surgical, and it cited a projection of nearly $12 billion in Intuitive Surgical revenue in 2026, which the outlet said would be roughly 12% of J&J’s projected annual sales.

More like this

Sources